Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lymphoma, Non-Hodgkin 1Fanconi Anemia 1Colorectal Neoplasms 1Anus Neoplasms 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × SRA737 × Lymphoid × Clear all
NCT02797964 2023-06-18

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
107 enrolled 20 charts
Classical hematologyGastrointestinalHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Fanconi Anemia, Lymphoma, Non-Hodgkin, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡